Background and Aims: Ulcerative colitis [UC] is a chronic inflammatory disease of the colon. Colonoscopy remains the gold standard for evaluating disease activity, as clinical symptoms are not sufficiently accurate. The aim of this study is to identify new accurate non-invasive biomarkers based on whole-blood transcriptomics that can predict mucosal lesions and response to treatment in UC patients. Methods: Whole-blood samples were collected for a total of 152 UC patients at endoscopy. Blood RNA from 25 UC individuals and 20 controls was analysed using microarrays. Genes that correlated with endoscopic activity were validated using real-time polymerase chain reaction in an independent group of 111 UC patients, and a prediction model for mucosal lesions was evaluated. Responsiveness to treatment was assessed in a longitudinal cohort of 16 UC patients who started anti-tumour necrosis factor [TNF] therapy and were followed up for 14 weeks. Results: Microarray analysis identified 122 genes significantly altered in the blood of endoscopically active UC patients. A significant correlation with the degree of endoscopic activity was observed in several genes, including HP, CD177, GPR84, and S100A12. Using HP as a predictor of endoscopic disease activity, an accuracy of 67.3% was observed, compared with 52.4%, 45.2%, and 30.3% for C-reactive protein, erythrocyte sedimentation rate, and platelet count, respectively. Finally, at 14 weeks of treatment, response to anti-TNF therapy induced alterations in blood HP, CD177, GPR84, and S100A12 transcripts that correlated with changes in endoscopic activity. Conclusions: Transcriptional changes in UC patients are sensitive to endoscopic improvement and appear to be an effective tool to monitor patients over time.
Usefulness of Transcriptional
which in most patients, follows a remitting and relapsing course. 2 Disease activity can be determined by assessments of clinical symptoms and endoscopic lesions. 3 Nonetheless, the potential discrepancies between clinical symptoms and endoscopic lesions, 4 as well as the association of mucosal healing with sustained remission and reduced surgery requirements, 2, 5 makes mucosal healing a therapeutic objective in UC management.
Although endoscopy is the gold standard for assessing disease activity and severity, it carries a considerable economic cost, discomfort for patients and, in severe cases, risk of procedure complications. Moreover, the need for endoscopic procedures may negatively impact on patient recruitment in clinical trials. Consequently, considerable efforts have been made to identify reliable non-invasive biomarkers that can predict disease activity. Available serological and faecal biomarkers, although widely used in clinical practice and clinical trials, have low diagnostic accuracy for the detection of ongoing inflammation, particularly in cases of mild or moderately active UC. [6] [7] [8] We and others have previously shown that transcriptional analysis of intestinal biopsies is a useful tool for identifying not only disease biomarkers, but also molecular mechanisms of intestinal inflammation. [9] [10] [11] [12] [13] Nonetheless, little evidence is available on the usefulness and reliability of transcriptional changes in whole-blood samples in patients suffering from inflammatory bowel disease [IBD] . 14 Here, we assess the sensitivity of whole-blood transcriptional changes to predict endoscopic lesions in UC. Whole-genome microarray analysis or real-time polymerase chain reaction [RT-PCR] of total blood was used in a total of 152 UC patients undergoing endoscopy to assess disease severity. Our study identifies and validates blood transcriptional biomarkers that can be used in clinical settings as predictors of endoscopic activity. Moreover, the sensitivity of the identified blood biomarkers as surrogate indicators of response to therapy was evaluated using a prospective cohort of patients receiving anti-tumour necrosis factor alpha [TNFα].
Materials and Methods
More detailed information is described in the supplementary materials and methods [available as Supplementary data at ECCO-JCC online].
Patient population and assessment of disease activity
Two cohorts of patients were included in this study. The first cohort came from a cross-sectional multicentre study, and included UC patients who had undergone clinical and endoscopic evaluations. Table 1 ]. Non-IBD controls were those subjects undergoing a screening colonoscopy for colorectal cancer and who had had a normal examination. The second cohort came from an observational prospective study at Hospital Clinic Barcelona [Spain] , and included UC patients who had been treated with an anti-TNFα antibody [infliximab, adalimumab or golimumab] and followed up for 14 weeks.
All patients underwent clinical and endoscopic evaluations at Weeks 0 and 14. From January 2013 to September 2015, 16 UC patients were included [ Table 2 ]. Patients with concomitant infections were excluded from both cohorts.
Institutional ethics committee approval was required in all centres and written informed consent was obtained for all patients.
As we hypothesised that changes in a systemic biomarker [such as a transcript in blood] may be influenced by the inflammatory burden [whole disease extension and activity at a given time point], 15 two different endoscopic scores were reported; the endoscopic Mayo score and the Modified Score [MS, sum of the endoscopic Mayo score for the five colonic segments]. 16 For those cases with incomplete colonoscopy [n = 16], the MS could not be calculated. Endoscopic remission was defined as an endoscopic Mayo score or MS = 0. 
Blood collection

Microarray
The derived cDNA from whole blood [Group 1, 23 was used. The logistic regression was used to predict endoscopic activity, and the lasso regression analysis method [least absolute shrinkage and selection operator] was performed for variable selection. 26 The receiver operating characteristic [ROC] area under the curve [AUC] was then calculated to assess the ability to detect mucosal lesions in our models, and the DeLong's test was used to determine significant Figure 2A ]. The higher the endoscopic Mayo score, the more flattened was the MS density function due to an increased range of disease extension. Examining the association of gene expression with the endoscopic disease activity, we identified 20 genes that significantly correlated with the endoscopic Mayo score and 18 genes that significantly correlated with MS [Spearman's rank correlation test, p < 0.05; rho > 0.2] [ Table 3 ]. A total of 16 genes were common, with HP, CD177, and GPR84 being those with the strongest relationship in both cases [ Figure 2B , C]. Also significant was the relationship with the inflammation-related molecule S100A12. Moreover, pairwise analysis of the interrogated genes revealed HP, CD177, and GPR84 as the only ones significantly regulated in patients with an endoscopic Mayo score of 2 compared with 0 [ Table 3 and Figure 2B] . None of the genes was able to detect changes between patients with an endoscopic Mayo score of 1 compared with 0.
Furthermore, the association between routinely used blood biomarkers [CRP, ESR, and platelet counts] and endoscopic disease activity was explored [Supplementary Table 3 and Figure 2D , E]. Although significant correlations of the biomarkers with disease severity were observed, pairwise analysis revealed significant changes when comparing mild, moderate, or severe activity with inactive UC only for CRP [elevated exclusively in severe disease]. Additionally, given the neutrophil-related signature we had identified, we explored the potential relationship between neutrophil counts and endoscopic disease activity and found no significant associations [Supplementary 
Haptoglobin [HP] is the best transcript for predicting mucosal lesions in UC patients
Within the subset of genes whose expression best correlates with endoscopic disease severity, we found HP as the best gene to predict the presence of active mucosal lesions in UC patients. 
Changes in blood transcriptional biomarkers correlate with response to anti-TNFα therapy
Finally, the ability of the identified transcriptional biomarkers [HP, CD177, GPR84, and S100A12] to evaluate changes in endoscopic activity in response to biological therapy was assessed. A cohort of UC patients with active disease starting anti-TNFα treatment [n = 16] were followed up over 14 weeks. Table 2 reports the clinical and endoscopic parameters at Weeks 0 and 14. Despite the fact that only four patients achieved an endoscopic Mayo score ≤ 1 at Week 14, a decrease in the global severity or extension of the endoscopic lesions was observed in the majority of cases. By reporting the MS, we identify a reduction of MS of at least 1 point in 10 cases, no changes in four, and worsening in two [ Figure 4A ]. In contrast, only five cases showed an endoscopic response based on the endoscopic Mayo score [reduction in endoscopic Mayo score of at least 1 point] and no changes were detected in the remaining cases. Furthermore, a better concordance is observed between the response based on the Global Mayo score and MS compared with the endoscopic Mayo score [ Supplementary  Figure 3 , available as Supplementary data at ECCO-JCC online]. This highlights the importance of reporting both disease extension and activity to accurately reflect changes in disease activity over time.
Importantly, we found that a decrease in the expression of HP, CD177, GPR84, and S100A12 was associated with a reduction in the MS. As shown in Figure 4B , the changes observed in the transcription of those genes permitted differentiation between those patients who, based on MS, endoscopically improved [blue dots] and those who worsened or did not change [red dots]. Interestingly, in two patients [black arrows], expression of the transcriptional biomarkers decreased at Week 14 despite no improvement in their MS. Although in both patients an improvement in the severity of the disease [a marked decrease in the number of ulcers] was reported, the ulcers persisted in all involved segments and therefore no change in the endoscopic score [endoscopic Mayo score of 3, or MS of 15 and 9] was noted. The behaviour of serological markers as well as serum HP protein before and after treatment was also evaluated and showed no significant association with the mucosal changes with the exception of CRP [ Table 2 and Figure 4C ].
Discussion
The importance of monitoring local inflammatory activity in IBD is becoming increasingly clear. There can, however, be discrepancies between clinical symptoms and the severity of mucosal lesions. In this context, clinical trials relying on clinical scores to assess activity at inclusion or efficacy as an endpoint, may result in high placebo response rates, as well as unreliable un-reproducible results. Blood transcriptional signatures have been explored in infectious and autoimmune systemic diseases and cancer. [36] [37] [38] [39] The use of whole-blood transcriptional analysis to detect disease activity nonetheless remains a largely unexplored tool in IBD. Compared with the dramatic transcriptional changes observed in the intestinal mucosa of patients with active inflammation, the degree of transcriptional regulation in blood, even in patients with severe disease, is remarkably low. This is not entirely unexpected, given that circulating cells may only partially reflect changes in the mucosa of UC patients. Nonetheless, using sensitive RT-PCR analysis, we can predict endoscopic mucosal lesions in patients with UC.
Our data reveal the important contribution of neutrophils to the systemic inflammatory response in UC patients. We show that expressions of neutrophil-related genes [including CD177, HP, S100A12, ARG1, and ANXA3], rather than total neutrophil numbers, are surrogate markers of endoscopic activity. Remarkably, an increase in serum and faecal concentrations of S100A12 protein had been previously shown to correlate with disease activity in IBD patients. 35, 40 In contrast, the increased levels of serum calprotectin [S100A8/A9], described as a new diagnostic and prognostic marker in IBD, 41 were not observed here at a transcriptional level. Similarly, the neutrophil gelatinase B-associated lipocalin [LCN2] and the matrix metalloproteinase-9 [MMP9] complex have been proposed as surrogate serum markers for assessing mucosal healing in UC, 42 but were not transcriptionally regulated in blood from our patient cohort. Along the same lines, whereas we identified HP transcript as a sensitive predictor of mucosal lesions and therapy response, changes in serum HP are not sensitive to such alterations. HP protein is primarily synthesised by hepatocytes 43 but it has also been described as a specific granule protein of neutrophils, 28 which could explain the transcript detection at the blood level and the moderate correlation between transcript and protein measurements [r = 0.40]. Altogether, this suggests that although changes in serum proteins due to disease activity can originate in other tissues [eg liver, intestine], transcription consistently reflects changes in the activation and abundance of cells present in the peripheral compartment. Therefore, blood transcription and serum protein concentrations may not necessarily reflect the same biological processes.
Besides secreted or granule-associated proteins, we also identified the cell membrane proteins CD177 and GPR84 as predictors of endoscopic lesions. CD177 is a neutrophil-specific GPI-anchored glycoprotein normally expressed on a subpopulation of neutrophils. 44 Although there are controversial results, the preferential recruitment of CD177 + neutrophils towards inflamed tissues has been suggested, 45 and the increased protein and transcripts for CD177 have been described in bacterial infections, polycythaemia vera, and ANCA-associated vasculitis as well as in response to G-CSF stimulation. 27, 46 Interestingly, elevated expression of both CD177 and HP genes in whole blood has been closely associated with ipilimumabinduced colitis in advanced melanoma patients, also suggesting that neutrophils potentially play a broader role in immune-related colonic disorders. 47 GPR84, mainly expressed by leukocytes, is a G protein-coupled receptor that has been described as a putative receptor for mediumchain fatty acids [MCFAs] which elicits neutrophil and macrophage chemotaxis. 29 The efficacy of inhibiting GPR84 has been studied in a mouse chronic colitis model and in human UC patients [clinical trial: NCT02337608]. Although a diminution of colonic lesions and a reduction in neutrophil infiltrate was observed in mouse, 48 results in human showed safety and tolerance but the study did not meet the efficacy endpoints. 49 Nevertheless, our data points to the potential use of this gene as a biomarker of disease activity.
Taken together, we provide insights on new and promising minimally invasive biomarkers capable of predicting endoscopic mucosal lesions in patients with UC. We realise that the lack of faecal calprotectin [FC] represents the major drawback of our study, as FC has demonstrated to be the best biomarker of endoscopic activity. 15 Despite considerable efforts to collect this biomarker in our study cohorts, there remained a large number of missing values, rendering it impossible to include this datum in the analysis and restricting our study to the use of other available biomarkers with poor correlation with endoscopic activity, like CRP, ESR, and platelet counts. The difficulties in FC sampling were also pointed out in the first clinical study that used FC as a primary endpoint. 50 Nonetheless, the results obtained by Sandborn et al. 51 regarding the ability of FC to predict endoscopic remission are remarkably similar to the prediction power of HP in our study [Supplementary File 1, available as Supplementary data at ECCO-JCC online]. Whereas additional studies should be done, as the total number of patients with endoscopically inactive disease in our cohort is limited, we would like to stress that with potentially comparable predictive values, whole-blood biomarkers can offer practical advantages in clinical practice compared with faecal biomarkers.
Another limitation, as distinct inflammatory mechanisms have been suggested between early and late inflammatory bowel diseases, [52] [53] [54] could be the difference in disease duration between our active and inactive patients. However, no significant correlation between disease duration and expression of the selected transcriptional biomarkers was found.
Importantly, our data reveal the sensitivity of the identified blood biomarkers to mirror changes in local inflammatory activity in UC patients following induction therapy. Although our results are promising, they are derived from a relatively small number of patients and restricted to anti-TNFα therapy. It will be necessary to validate the usefulness of the identified biomarkers in predicting response to drugs with mechanisms of action that differ from those of TNFα blockade. Interestingly, whole-blood CD177, HP, and GPR84 transcripts were found at higher levels in corticosteroid-resistant children with severe UC compared with corticosteroid-responsive children, 14 suggesting these are also sensitive to the effect of corticosteroids.
In summary, our study has the merit of assessing in a multicentric cohort the usefulness of transcriptional blood analysis to predict endoscopic disease activity. By starting with a whole-genome approach, we were able to identify transcripts with the potential to change based on the presence of endoscopic lesions. Importantly, we validated a subset of genes in a large group of patients with a wide range of endoscopic activity and disease extent. More importantly, the transcriptional blood biomarkers were tested for responsiveness in a prospective cohort and proved to be sensitive to changes in endoscopic disease activity.
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